Molecular Diagnostics
|
Open Access
Featured
-
-
Translational Therapeutics
| Open AccessTargeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
- Chiao-En Wu
- , Arman Esfandiari
- & John Lunec
-
Molecular Diagnostics
| Open AccessFavourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients
- D Zugna
- , R Senetta
- & S Ribero
-
Molecular Diagnostics
| Open AccessPrognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma
- Emilia Hugdahl
- , May Britt Kalvenes
- & Lars A Akslen
-
Epidemiology
| Open AccessTetracycline use and risk of incident skin cancer: a prospective study
- Wen-Qing Li
- , Aaron M Drucker
- & Abrar A Qureshi
-
Molecular Diagnostics
| Open AccessCharacterisation of the cancer-associated glucocorticoid system: key role of 11β-hydroxysteroid dehydrogenase type 2
- Nicola Cirillo
- , David J Morgan
- & Stephen S Prime
-
Molecular Diagnostics
| Open AccessTumour mutation status and sites of metastasis in patients with cutaneous melanoma
- Nikki R Adler
- , Rory Wolfe
- & Victoria J Mar
-
Translational Therapeutics
| Open AccessModulating cancer cell survival by targeting intracellular cholesterol transport
- Omer F Kuzu
- , Raghavendra Gowda
- & Gavin P Robertson
-
Molecular Diagnostics
| Open AccessUV radiation promotes melanoma dissemination mediated by the sequential reaction axis of cathepsins–TGF-β1–FAP-α
- Petra Wäster
- , Kyriakos Orfanidis
- & Karin Öllinger
-
Translational Therapeutics
| Open AccessEfficacy of anti-PD-1 therapy in patients with melanoma brain metastases
- Sagun Parakh
- , John J Park
- & Matteo S Carlino
-
Molecular Diagnostics
| Open AccessMutation status among patients with sinonasal mucosal melanoma and its impact on survival
- Moran Amit
- , Samantha Tam
- & Ehab Y Hanna
-
Letter to the Editor
| Open AccessComment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’
- Keisuke Imafuku
- , Koji Yoshino
- & Hiroo Hata
-
Letter to the Editor
| Open AccessReply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’
- Samantha Bowyer
- , Prashanth Prithviraj
- & Oliver Klein
-
Clinical Study
| Open AccessEvaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
- Adi Nosrati
- , Katy K Tsai
- & Adil Daud
-
Letter to the Editor
| Open AccessReply to ‘Comment on ‘The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation’’ – outdoor occupation may not be linked to increased risk of melanoma in Britain
- Lesley Rushton
- & Sally J Hutchings
-
Clinical Study
| Open AccessPhase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
- Adil Daud
- , Harriet M Kluger
- & Geoffrey I Shapiro
-
Epidemiology
| Open AccessThe burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation
- Lesley Rushton
- & Sally J Hutchings
-
Clinical Study
| Open AccessThe impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
- Louise E Daly
- , Derek G Power
- & Aoife M Ryan
-
Epidemiology
| Open AccessHistory of chronic inflammatory disorders increases the risk of Merkel cell carcinoma, but does not correlate with Merkel cell polyomavirus infection
- Helka Sahi
- , Harri Sihto
- & Eero Pukkala
-
Epidemiology
| Open AccessInterval cancers after skin cancer screening: incidence, tumour characteristics and risk factors for cutaneous melanoma
- J Hübner
- , A Waldmann
- & A Katalinic
-
Epidemiology
| Open AccessHeight, height-related SNPs, and risk of non-melanoma skin cancer
- Xin Li
- , Liming Liang
- & Jiali Han
-
Mini Review
| Open AccessIn the Wnt-er of life: Wnt signalling in melanoma and ageing
- Amanpreet Kaur
- , Marie R Webster
- & Ashani T Weeraratna
-
Short Communication
| Open AccessCessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
- Matteo S Carlino
- , Vito Vanella
- & Paolo A Ascierto
-
Translational Therapeutics
| Open AccessComparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer
- Ana Luiza Ribeiro de Souza
- , Kayla Marra
- & Brian W Pogue
-
Epidemiology
| Open AccessUse of sildenafil or other phosphodiesterase inhibitors and risk of melanoma
- Anton Pottegård
- , Sigrún Alba Johannesdottir Schmidt
- & Laurel A Habel
-
Molecular Diagnostics
| Open AccessA UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma
- Michelle Chin I Lo
- , Anna Paterson
- & Laszlo Igali
-
Mini Review
| Open AccessMolecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies
- Shivshankari Rajkumar
- & Ian R Watson
-
Clinical Study
| Open AccessFirst-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma
- C Le Tourneau
- , B Dreno
- & M Dutreix
-
Clinical Study
| Open AccessEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
- S Bowyer
- , P Prithviraj
- & O Klein
-
Clinical Study
| Open AccessImmunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients
- Angelica Loskog
- , Aglaia Maleka
- & Gustav Ullenhag
-
Translational Therapeutics
| Open AccessOptimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
- Sonya C Tate
- , Teresa F Burke
- & Damien M Cronier
-
Molecular Diagnostics
| Open AccessBRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival
- Emilia Hugdahl
- , May Britt Kalvenes
- & Lars A Akslen
-
Molecular Diagnostics
| Open AccessPhosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma
- Julia H Carter
- , James A Deddens
- & Jeremy R Graff
-
Clinical Study
| Open AccessSerum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
- S Diem
- , B Kasenda
- & J Larkin
-
Epidemiology
| Open AccessRelation of statin use with non-melanoma skin cancer: prospective results from the Women’s Health Initiative
- Ange Wang
- , Marcia L Stefanick
- & Jean Y Tang
-
Molecular Diagnostics
| Open AccessMelanoma-expressed CD70 is involved in invasion and metastasis
- Christine Pich
- , Guillaume Sarrabayrouse
- & Anne-Françoise Tilkin-Mariamé
-
Translational Therapeutics
| Open AccessInterplay between cadherins and α2β1 integrin differentially regulates melanoma cell invasion
- Carole Siret
- , Chloé Terciolo
- & Frédéric André
-
Clinical Study
| Open AccessThe melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma
- Anna Wilkins
- , Andrew Furness
- & Kevin Harrington
-
Molecular Diagnostics
| Open AccessOverexpression of connexin 43 reduces melanoma proliferative and metastatic capacity
- A Tittarelli
- , I Guerrero
- & F Salazar-Onfray
-
Short Communication
| Open AccessPersonal history of rosacea and risk of incident cancer among women in the US
- W-Q Li
- , M Zhang
- & A A Qureshi
-
Genetics and Genomics
| Open AccessMC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project
- E Tagliabue
- , M C Fargnoli
- & S Raimondi
-
Molecular Diagnostics
| Open AccessSNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma
- P El Hajj
- , D Gilot
- & F Journe
-
Translational Therapeutics
| Open AccessBaseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
- P F Ferrucci
- , S Gandini
- & C Martinoli
-
Molecular Diagnostics
| Open AccessInterleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis
- S K Srivastava
- , A Bhardwaj
- & S Singh
-
Clinical Study
| Open AccessThe combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial
- A P Algazi
- , E Cha
- & A I Daud
-
Full Paper
| Open AccessEstimating the potential survival gains by eliminating socioeconomic and sex inequalities in stage at diagnosis of melanoma
- M J Rutherford
- , L Ironmonger
- & P C Lambert
-
Molecular Diagnostics
| Open AccessOverexpression of nucleostemin contributes to an advanced malignant phenotype and a poor prognosis in oral squamous cell carcinoma
- R Yoshida
- , H Nakayama
- & T Ito
-
Short Communication
| Open AccessStatin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark
- S Arnspang
- , A Pottegård
- & D Gaist
-
Epidemiology
| Open AccessSeasonal variation in the month of birth in patients with skin cancer
- F La Rosa
- , A Liso
- & F Stracci
-
Mini Review
| Open AccessNovel functions of chromatin-bound IκBα in oncogenic transformation
- L Espinosa
- , A Bigas
- & M C Mulero